Policy Statement

Use of intraoperative radiotherapy (IORT) may be considered medically necessary in either of the following situation (see Policy Guidelines section related to breast cancer):

- Rectal cancer with positive or close margins with T4 lesions
- Recurrent rectal cancer

Use of intraoperative radiotherapy is considered investigational for all other oncologic applications, including but not limited to breast cancer.

Policy Guidelines

This policy does not address the use of IORT for breast cancer (see Blue Shield of California Medical Policy: Accelerated Breast Irradiation and Brachytherapy Boost After Breast-Conserving Surgery for Early-Stage Breast Cancer).

Coding

There are specific CPT codes for intraoperative radiotherapy:

- 77424: Intraoperative radiation treatment delivery, x-ray, single treatment session
- 77425: Intraoperative radiation treatment delivery, electrons, single treatment session
- 77469: Intraoperative radiation treatment management

Description

Intraoperative radiotherapy (IORT) is delivered directly to exposed tissues during surgery and may allow higher radiation doses by excluding nearby radiation dose-sensitive tissues. IORT can be delivered by electron beams produced by linear accelerators or high-dose rate brachytherapy.

Related Policies

- Accelerated Breast Irradiation and Brachytherapy Boost After Breast-Conserving Surgery for Early-Stage Breast Cancer

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.
**Regulatory Status**

The INTRABEAM® system was first approved for use by the U.S. Food and Drug Administration for intracranial tumors in 1999 and was subsequently approved for whole body use in 2005. INTRABEAM® spherical applicators are indicated for use with the INTRABEAM® system to deliver a prescribed dose of radiation to the treatment margin or tumor bed during intracavity radiotherapy or IORT treatments. In 1998, the Mobetron® mobile electron beam accelerator, designed for use during surgery, was cleared for marketing by the Food and Drug Administration through the 510(k) process. Food and Drug Administration product codes: JAD, LHN.

This evidence review does not address the use of IORT for breast cancer (see Blue Shield of California Medical Policy: Accelerated Breast Irradiation and Brachytherapy Boost After Breast-Conserving Surgery for Early-Stage Breast Cancer).

**Rationale**

**Background**

Intraoperative radiotherapy (IORT) increases the intensity of radiation delivered directly to tumors. The tumor and associated tissues at risk for micrometastatic spread are directly visualized during surgery. IORT is delivered directly to the tumor, and normal or uninvolved tissues are not exposed to radiation because they are removed or shielded from the treatment field.

**Literature Review**

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function-including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, two domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

**Intraoperative Radiotherapy for Various Cancers**

**Clinical Context and Therapy Purpose**

The purpose of IORT in patients who have cancer is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does IORT improve the net health outcome when used as an adjunct to surgery and external-beam radiotherapy (EBRT) and when used to reduce radiation toxicity?

The following PICOs were used to select literature to inform this review.
Patients
The relevant population of interest are patients undergoing tumor resection. The specific populations addressed in this evidence review are individuals with rectal cancer, gastric cancer, soft tissue sarcomas, gynecologic cancers, head and neck cancers, pancreatic cancer, renal cell carcinoma, glioblastoma, neuroblastoma, or fibromatosis.

Classification of surgical resection margins are listed in Table 1.

<table>
<thead>
<tr>
<th>Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>R0</td>
<td>Negative margins; no cancer cells detected in resected tissue</td>
</tr>
<tr>
<td>R1</td>
<td>Microscopic positive margin; cancer cells detected by microscope in resected tissue</td>
</tr>
<tr>
<td>R2</td>
<td>Macroscopic positive margin; tumor cells detected without microscope in resected tissue</td>
</tr>
</tbody>
</table>

Interventions
The therapy being considered is IORT. IORT can be delivered by electron beams produced by linear accelerators (intraoperative electron beam therapy), or high-dose rate brachytherapy. Most clinical experience involves intraoperative electron beam therapy.

IORT is performed with applicators and cones that attach to the treatment head of high-energy medical linear accelerators that are designed to direct radiation to defined surface structures.

Comparators
The following therapies and practices are currently being used to make decisions about patients with cancer: surgery alone, multimodal therapies (EBRT plus surgery or chemotherapy).

Most patients receive preoperative or postoperative EBRT in addition to surgical resection of the tumor. Therefore, IORT would be considered an adjuvant treatment to multimodal treatment that includes surgery plus EBRT. For recurrent tumors already treated with EBRT, and tissue at risk for radiation toxicity (e.g., head and neck cancers), IORT is being evaluated in conjunction with surgery alone.

Outcomes
The general outcomes of interest are overall survival (OS), disease-specific survival, and harms from treatment, specifically radiation toxicity. Radiation toxicity would be measured in weeks or months after treatment while OS and disease-specific survival would be measured over one to ten years, depending on specific cancer.

Rectal Cancer
Randomized Controlled Trials
The only RCT identified is the multicenter study evaluating IORT for locally advanced rectal cancer by Dubois et al (2011). It was included in the meta-analyses described next. Patients (n=142) with locally advanced rectal cancer were treated with preoperative radiotherapy and randomized to surgical resection alone or surgical resection plus IORT. Mean duration without local relapse, based on Kaplan-Meier analysis, was 107 months with surgery plus IORT and 126 months with surgery alone (p=0.602). There was no significant difference between groups in the incidence of local control or OS.

Systematic Reviews
Several reviews have evaluated IORT for colorectal cancer (CRC). Wiig et al (2014) found no evidence that IORT is beneficial for primary rectal cancer. Reviewers selected 18 studies on primary rectal cancer (including 1 RCT, 5 comparative trials, 5 trials without IORT) and 18 studies on locally recurrent rectal cancer (including 5 studies without IORT). The indications for IORT varied, and meta-analysis was not performed due to heterogeneity in study designs and reporting. Results suggested IORT provided no OS benefit for primary completely resected rectal cancers, with a possible reduction in local recurrence in cases of incomplete tumor resection.
There was no evidence that IORT affected OS or local recurrence when used to treat locally recurrent rectal cancer. Results were limited by the risk of selection bias for IORT in nonrandomized studies as well as variability in stages and IORT dosing.

Mirnezami et al (2013) conducted a systematic review and meta-analysis on the use of IORT for advanced or recurrent CRC. Reviewers included 29 studies (14 prospective, 15 retrospective) published between 1965 and 2011 (total n=3003 patients). Indications for IORT were locally advanced disease in 1792 patients and locally recurrent disease in 1211 patients. Comparative studies found a significant effect favoring IORT for improved local control (odds ratio [OR], 0.22; 95% confidence interval [CI], 0.05 to 0.86; p=0.03), disease-free survival (DFS; hazard ratio [HR], 0.51; 95% CI, 0.31 to 0.85; p=0.009), and OS (HR=0.33; 95% CI, 0.2 to 0.54; p=0.001). With IORT, no increase was observed in total (OR=1.13; 95% CI, 0.77 to 1.65; p=0.57), urologic (OR=1.35; 95% CI, 0.84 to 2.82; p=0.47), or anastomotic (OR=0.94; 95% CI, 0.42 to 2.1; p=0.98) complications; however, increased wound complications were noted after IORT (OR=1.86; 95% CI, 1.03 to 3.38; p=0.049).

Nonrandomized Comparative Studies
Zhang et al (2015) reported on a nonrandomized comparative study of 148 patients who had primary locally advanced rectal cancer treated with IORT plus EBRT or EBRT alone. Use of IORT was based on patient preference and available technology; thus, there was a high-risk of selection bias. Five-year local control was 89.7% for IORT plus EBRT compared with 79.2% for EBRT alone (p=0.032). DFS was also increased in the IORT group (69%) compared with IORT alone (58.5% p=0.049). However, OS rates did not differ significantly between groups. Multivariate analysis found a significant impact on tumor size classification and staging, with a trend (p=0.079) for improved locoregional control with IORT, and no significant differences between groups in acute and late toxicity.

Observational Studies
A large series was reported by Haddock et al (2011) for patients treated from 1981 through early 2008. Six hundred seven patients with recurrent CRC received IORT as a component of treatment. IORT was preceded or followed by EBRT in 583 (96%) patients. Resection was classified as R0 in 227 (37%) and R1 in 224 (37%). Median OS was 36 months. Five- and 10-year survival rates were 30% and 16% respectively. Survival estimates at 5 years were 46% and 27% for R0 and R1 resections, respectively. Multivariate analysis revealed that R0 resection, no prior chemotherapy, and more recent treatment (in the second half of the series) were associated with improved survival. Three-year cumulative incidence rates of central (within the IORT field), local, and distant relapse were 12% 23%, and 49%, respectively. Toxicity grade 3 or higher partially attributable to IORT was observed in 66 (11%) patients.

Section Summary: Rectal Cancer
The evidence for IORT as part of a multimodal treatment approach in patients who have CRC includes an RCT, nonrandomized comparative studies, and systematic reviews of these studies. Adjunctive use of IORT could permit an increase in radiation dose without increasing complications. However, a phase 3 RCT and meta-analysis of locally advanced CRC did not report improved outcomes with IORT in combination with preoperative EBRT and surgery. Nonrandomized comparative studies have shown some benefit in health outcomes with adjunctive IORT; however, these studies were limited by a high-risk of selection bias, heterogeneous patient populations, and heterogeneous delivery of other treatments. RCTs are needed to determine the effect of adjunctive IORT for locally advanced or recurrent rectal tumors with greater certainty.

Gastric Cancer
Systematic Reviews
A meta-analysis by Yu et al (2015) assessed 8 RCTs that used IORT for resectable gastric cancer. The literature search from 1990 through mid-2013 identified trials that assigned patients to surgery plus IORT or to surgery without IORT. Three studies also gave EBRT to both arms. HRs to describe
the impact of adjuvant IORT on OS and locoregional control were obtained directly from the original studies or calculated from survival curves. Compiled data from 4 studies that reported OS revealed that IORT had no significant impact on OS (HR=0.97; 95% CI, 0.75 to 1.26; p=0.837). Notably, three of the four studies provided adjuvant EBRT. In another 3 studies that tested the efficacy of IORT for OS in patients with stage III disease, OS significantly improved (HR=0.60; 95% CI, 0.40 to 0.89; p=0.011). However, all three of these studies did not administer EBRT and used a higher dose of IORT than the other studies. The largest study in the meta-analysis included 292 patients with stage III disease. The HR for OS in this study was 0.54 (95% CI, 0.35 to 0.83). Significant improvement in locoregional control was observed in 4 studies that provided such data (HR=0.40; 95% CI, 0.26 to 0.62; p<0.001).

**Section Summary: Gastric Cancer**

A meta-analysis of eight RCTs found a benefit of IORT in locoregional control but not OS when used in combination with EBRT. Three studies found improved OS in patients with stage III disease; however, none of the three studies provided EBRT. Randomized studies comparing the benefits and harms of IORT and EBRT are needed to determine the efficacy of IORT with greater certainty. It cannot be determined from the current literature whether IORT in patients with stage III disease provides any benefit for OS when used with EBRT.

**Soft Tissue Sarcomas**

**Systematic Reviews**

A systematic review by Skandarajah et al (2009) highlights the potential value of IORT in the multimodal treatment of retroperitoneal sarcoma because these tumors are often close to dose-limiting structures, but reviewers noted that it is not without complications. 

**Randomized Controlled Trials**

One small randomized trial (n=35), reported by Sindelar et al (1993), compared IORT plus low-dose (35- to 40-gray) postoperative EBRT with high-dose (50- to 55-gray) EBRT alone. The local recurrence rate was lower (40%) in the combined therapy group than in the EBRT-only group (80%), with no difference in OS. Patients who received IORT had fewer radiation enteritis events but had more disabling peripheral neuropathies.

**Nonrandomized Comparative Studies**

In a nonrandomized comparative study of 251 patients, 92 of whom received IORT, Lehnert et al (2000) reported that IORT patients had more surgical complications and significantly more infectious complications; however, the IORT-treated patients had a 40% lower rate of local recurrence. IORT demonstrated effective tumor control in osteosarcoma.

A multicenter study by Calvo et al (2014) compared outcomes from 159 patients who had soft tissue sarcomas of the extremity treated using IORT plus multimodal therapy with 95 patients treated using multimodal therapy without IORT. IORT was administered to patients who had close (<1 cm) or positive surgical margins while patients with margins of 1 cm or greater were treated only with multimodal therapy. Use of IORT in the high-risk patients led to 5-year local control (82%) and OS rates (72%) that were similar to lower-risk sarcoma patients treated without IORT. DFS (62%) remained modest due to the high-risk of distant metastases. In multivariate analysis, only surgical margin resection was significantly associated with local control.

Stucky et al (2014) reported on 63 consecutive patients with retroperitoneal sarcoma treated with surgery plus IORT (n=37) or surgery-only (n=26) between 1996 and 2011. Median follow-up was 45 months. The 5-year local control rate for patients receiving surgery plus IORT was 89% and 46% for the surgery-only patients (p=0.03). Survival did not differ as both groups had an actutimes 5-year OS rate of 60%. The contribution of IORT cannot be determined from this study.

**Section Summary: Soft Tissue Sarcomas**

The evidence on the use of adjunctive IORT for the treatment of soft tissue sarcomas includes a systematic review, a small RCT, and several nonrandomized comparative studies. Overall, study
quality was low. The limited data available would suggest that IORT might improve local control and OS but adverse events might outweigh any treatment benefit. RCTs are needed to determine the risks and benefits of IORT for soft tissue sarcomas with greater certainty.

**Gynecologic Cancers**

The literature on IORT for gynecologic cancers consists primarily of case series.

In a phase 2 trial, Giorda et al (2011) examined the use of radical surgery with IORT after chemotherapy in extracervical, locally advanced cancer patients. Between 2000 and 2007, 42 locally advanced cervical cancer patients were treated. EBRT was administered to the whole pelvic region in combination with chemotherapy. After EBRT and chemotherapy, 35 (83%) of 42 patients underwent radical surgery and IORT treatment. Five-year DFS and OS rates were 46% and 49% respectively. DFS and OS were significantly longer when the residual tumor was absent or limited to the cervix. At follow-up, only 3 (9%) of 35 patients were alive and free of disease.

A case series of 67 patients with locally advanced (n=31) and recurrent cervical cancer (n=36) treated with IORT at a Spanish center was reported by Martinez-Monge et al (2001). Previously unirradiated patients received preoperative chemoradiation. The 10-year control rate within the area treated with IORT was 69.4% for the entire group, 98.2% for the primary group, and 46.4% for the recurrent group. Control in the treated area correlated with margin status, amount of residual disease, and pelvic lymph node involvement. The overall incidence of toxic events attributable to IORT was 13.9%. The 10-year survival rate for the entire group was 34%, 58% for patients with primary disease, and 14% for those with recurrent disease. Patients, especially those with recurrent disease, with positive lymph nodes, parametrial involvement, and/or incomplete resection had poor local control, despite IORT at the doses used in the study.

Gao et al (2011) evaluated clinical outcomes and toxicity of IORT plus EBRT in advanced and recurrent ovarian carcinoma. All 45 patients in this series underwent optimal cytoreductive surgery. At 5-year follow-up, local control was observed in 68.9%, with OS and DFS rates of 64% and 56% respectively. The major complication was peripheral neuropathy, affecting 5 (11%) of patients.

**Section Summary: Gynecologic Cancers**

The literature on IORT for gynecologic cancers consists of a nonrandomized trial and case series. The contribution of adjuvant IORT cannot be determined from these studies. OS rates in patients with locally advanced or recurrent disease are low and reported complications can be severe.

**Head and Neck Cancers**

Zeidan et al (2011, 2012) reported on 2 case series of head and neck cancers. In the 2011 publication, they reported on the use of IORT for 231 patients with advanced cervical metastasis. OS rates at 1, 3, and 5 were 58%, 34%, and 26%, respectively. Recurrence-free survival rates at 1, 3, and 5 years were 66%, 55%, and 49%, respectively. A second publication reviewed the use of IORT in 96 patients with primary or recurrent cancer of the parotid gland. Recurrence-free survival rates at 1, 3, and 5 years were 82%, 69%, and 65% respectively. One-, 3-, and 5-year OS rates after surgery and IORT were 88%, 66%, and 56% respectively. Complications developed in 26 patients.

Thirty-four patients with recurrent head and neck cancer treated with IORT at another center were reported by Perry et al (2010). At a median follow-up of 23 months (range, 6-54 months), 8 patients were alive and without evidence of disease. The 1- and 2-year estimates for in-field local progression-free survival rates were 66% and 56%, respectively, with 13 (34%) in-field recurrences. One- and 2-year distant metastases-free survival rates were 81% and 62%, respectively, with 10 (29%) patients developing distant failure. One- and 2-year OS rates were 73% and 55% respectively, with a median time to OS of 24 months.
Chen et al (2008) reported on a retrospective study of 99 patients with locally recurrent salivary gland carcinomas treated surgically with or without IORT. All patients had previously been treated with surgery, and 82% had received postoperative EBRT. Median time from the initial surgery to local recurrence was 3.1 years. After salvage surgery, 37 (37%) patients received IORT. Reasons for IORT use were not clearly described in the report. For the entire patient population, the 1-, 3-, and 5-year estimates of local control were 88%, 75%, and 69%, respectively. Univariate analysis revealed predictors of local recurrence to be positive surgical margins, tumor size greater than 4 cm, and lack of IORT. Six of 37 patients treated with IORT experienced a local recurrence compared with 26 of 32 treated without IORT. At 5 years, the OS rate was 34%, and the DFS rate was 46%. The only predictor of DFS was the use of IORT, with a 5-year DFS rate of 61% in patients treated with IORT and 44% in patients without IORT. Complications were not analyzed.

A case series of 137 patients with persistent or recurrent salivary gland tumors treated with IORT after surgical resection was also reported by Chen et al (2007). There is a potential for overlap of patients with the Chen et al (2008) study described above. Eighty-three percent had previously received EBRT. Surgical margins were microscopically positive in 56 patients. Median follow-up among surviving patients was 41 months (range, 3-122 months). One-, 2-, and 3-year estimates of in-field control after surgery and IORT were 70%, 64%, and 61%, respectively, and positive margins at the time of IORT predicted in-field failure. Three-year rates of locoregional control, distant metastasis-free survival, and OS were 51%, 46%, and 36% respectively.

**Section Summary: Head and Neck Cancers**

The evidence on the use of IORT for head and neck cancers includes case series. The strongest evidence is from a retrospective study of patients who had recurrent salivary gland carcinomas and were at risk of radiation toxicity due to prior treatment with EBRT. In this study, multivariate analysis found that the use of IORT was a significant predictor of improved outcomes. However, the reasons for using or not using IORT were not clearly described, and there was a risk of selection bias.

**Pancreatic Cancer**

**Systematic Reviews**

Zygogianni et al (2011) conducted a review of the literature on the effectiveness and safety of IORT for pancreatic cancer. Reviewers assessed the potential impact of IORT on local control, quality of life, and OS. PubMed was searched from 1980 until 2010, and the search restricted to articles published in English. Thirteen studies were included. Results provided no clear evidence to indicate that IORT was more effective than other therapies in treating pancreatic cancer.

In a systematic review of the literature from 1995 to 2007, Ruano-Ravina et al (2008) assessed the efficacy and safety of IORT for pancreatic cancer. Inclusion criteria were studies with a minimum of 30 patients and survival results based on a minimum 3-month follow-up. Fourteen articles were selected: one was an IORT technology assessment report, five were cohort studies, and eight were case series studies, two of which belonged to the same series. None assessed quality of life. In general, the studies showed that IORT was associated with slightly increased survival among patients with pancreatic cancer in localized stages. However, no clear evidence indicated that IORT was more effective than other therapies in treating pancreatic cancer in locally advanced and metastatic stages.

**Case Series**

Jingu et al (2012) reported on a 30-year experience with the use of IORT for pancreatic cancer. One hundred ninety-two patients who had no distant organ metastases or dissemination at the time of laparotomy were enrolled. Fifty-five patients underwent adjuvant EBRT plus IORT, and 124 received adjuvant chemotherapy. Median follow-up was 37.5 months. At the time of the analysis, 166 patients had recurrent disease, and 35 had a local failure. Two-year local control and OS rates were 71.0% and 16.9%, respectively. A multivariate analysis showed that the degree of resection (R0 to R1 vs R2) and adjuvant chemotherapy both had a significant impact on OS.
gastrointestinal morbidity of Common Terminology Criteria for Adverse Events grade 4 or 5 was observed in four patients.

Another large series, conducted in Japan by Ogawa et al (2010), retrospectively analyzed 210 patients treated with IORT after resection of pancreatic cancer (R0, 147 patients; R1, 63 patients). Twenty-four patients also had postoperative EBRT, and 114 patients had chemotherapy. Median follow-up for the surviving 62 patients was 26.3 months (range, 2.7-90.5 months). At the time of analysis, 150 patients had disease recurrences, and the 2-year local control rate was 83.7%. Median survival time and the 2-year actutimes OS in all 210 patients were 19.1 months and 42%, respectively.

Section Summary: Pancreatic Cancer
The evidence on the use of IORT for pancreatic cancer includes large case series and systematic reviews of cohorts and case series. The systematic reviews found no evidence that IORT was more effective than other therapies in treating pancreatic cancer. No evidence was identified that evaluated outcomes when IORT was and was not added to multimodal therapy. Two-year OS rates in the large case series ranged from 16.9% to 42%.

Renal Cell Carcinoma
The evidence on IORT for renal cell carcinoma (RCC) includes case series. Paly et al (2014) reported on 98 advanced or locally recurrent RCC patients treated with IORT during nephrectomy at 9 different institutions during the period of 1985 and 2010. Pre- or postoperative EBRT was given to 62% of patients. Median follow-up time was 3.5 years for surviving patients. For advanced disease, the 5-year OS, disease-specific survival, and DFS rates were 37%, 41%, and 39%, respectively. For locally recurrent disease, the 5-year OS, disease-specific survival, and DFS rates were 55%, 60%, and 52%, and reported to be favorable to patients who had resection without IORT.

Calvo et al (2013) reported on 20-year outcomes in 25 patients with advanced (n=15) or recurrent (n=10) RCC treated with IORT. Fifteen (60%) patients received perioperative EBRT. Surgical resection resulted in negative margins (R0) in 6 (24%) patients and residual microscopic disease (R1) in 19 (76%) patients. Median follow-up for surviving patients was 22.2 years (range, 3.6-26 years). OS and DFS rates at 5 and 10 years were 38% and 18% and 19% and 14%, respectively. Locoregional control (tumor bed or regional lymph nodes) and distant metastases-free survival rates at 5 years were 80% and 22%, respectively. Six (24%) patients experienced acute or late toxicities of grade 3 or higher using National Cancer Institute Common Toxicity Criteria version 4.

Hallemeier et al (2012) reported on outcomes of a multimodality therapy combining maximal surgical resection, EBRT, and IORT for 22 patients with advanced or recurrent RCC. Surgical resection was R0 (negative margins) in 5 patients (23%) and R1 (residual microscopic disease) in 17 patients (77%). OS rates at 1, 5, and 10 years were 91%, 40%, and 35% and DFS rates at 1, 5, and 10 years were 64%, 31%, and 31% respectively. Central recurrence (within the IORT field), locoregional relapse (tumor bed or regional lymph nodes), and distant metastases rates at 5 years were 9%, 27%, and 64%, respectively.

Section Summary: Renal Cell Carcinoma
The evidence on the use of IORT for RCC includes case series. No controlled trials were identified to determine whether adjunctive IORT improves health outcomes when added to multimodal therapy with surgical resection and EBRT. In a case series, grade 3 or higher toxicity was reported in 24% of patients after IORT.

Glioblastoma
Nemoto et al (2002) reported on treatment with IORT for 32 patients with previously untreated malignant gliomas over a 10-year period. Patients also had postoperative radiotherapy. Eleven patients had histologic diagnoses of anaplastic astrocytoma, and 21 had glioblastoma.
Median survival time was 24.7 months in the anaplastic astrocytoma group and 33.6 months for matched historical controls. Differences in 1-, 2-, and 5-year survival rates between IORT-treated patients and historical controls were also not statistically significant. In the glioblastoma group, median survival was 13.3 months for IORT-treated patients and 14.6 months for matched controls. Data on 1-, 2-, and 5-year survival rates also did not differ significantly between groups.

**Section Summary: Glioblastoma**

Compared with historical controls, IORT for patients with previously untreated malignant gliomas had no survival benefit when given as an adjunct to surgery and EBRT.

**Neuroblastoma**

Rich et al (2011) reported on their experience using IORT after re-resection in patients with locally recurrent or persistent high-risk neuroblastomas. They retrospectively reviewed 44 consecutive patients who received IORT at a single institution between 2000 and 2009 after gross total resection of there current or persistent tumor. Median follow-up after IORT was 10.5 months. Each patient had received prior chemotherapy and surgery, and 94.5% had received EBRT. Median OS was 18.7 months (95% CI, 11.7 to 25.6 months), with a 50.4% probability of local control.

**Section Summary: Neuroblastoma**

No controlled trials were identified. There is insufficient evidence to evaluate the efficacy of IORT as an adjunct to multimodal therapy for neuroblastomas.

**Fibromatosis**

Roeder et al (2010) reviewed outcomes of 30 patients (31 lesions) with aggressive fibromatosis who were treated with IORT after surgery. Treatment with IORT was undertaken to avoid mutilating surgical procedures when complete surgical removal seemed to be unlikely or impossible. Median age was 31 years (range, 13-59 years). Resection status was a close margin in 6 lesions, microscopically positive in 13, and macroscopically positive in 12. Median tumor size was 9 cm. Twenty-five (83%) patients received additional EBRT. After a median follow-up of 32 months (range, 3-139 months), no disease-related deaths occurred. Five local recurrences were reported, resulting in actuatimes 3-year local control rates of 82% overall and 91% inside the IORT areas. Trends to improved local control were seen for age (>31 years) and negative surgical margins but none of these factors were statistically significant. Perioperative complications were found in six patients (wound healing disturbances in five patients, venous thrombosis in one patient). Late toxicity was seen in 5 (17%) patients.

**Section Summary: Fibromatosis**

Although the local control rate for aggressive fibromatosis is high in patients who have had incomplete surgery and EBRT, no controlled trials were identified that evaluated whether IORT improves survival. Late toxicity was observed with the combined treatment in 17% of patients.

**Summary of Evidence**

For individuals who have rectal cancer who receive adjunctive IORT, the evidence includes an RCT, nonrandomized comparative studies, and systematic reviews of these studies. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. Adjunctive use of IORT as part of a multimodal treatment could permit an increase in radiation dose without increasing complications. However, a phase 3 RCT and meta-analysis of IORT for locally advanced rectal cancer did not find improved outcomes with IORT in combination with EBRT and surgery. Nonrandomized comparative studies and a meta-analysis of these studies have shown some benefit in health outcomes with adjunctive IORT for recurrent rectal cancer, but these studies are limited by a high-risk of selection bias, heterogeneous patient populations, and heterogeneous delivery of other treatments. Large RCTs are needed to determine the effect of IORT with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have gastric cancer who receive adjunctive IORT, the evidence includes RCTs and a systematic review of RCTs. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. A meta-analysis of eight RCTs found a benefit of IORT in locoregional control (but not OS) when used with EBRT. When IORT was administered without adjuvant EBRT in patients with stage III disease, OS improved. Thus, IORT might be considered an alternative to EBRT in patients undergoing surgery for stage III gastric cancer. Randomized studies comparing the benefits and harms of the two treatments are needed to determine the efficacy of IORT with greater certainty. It cannot be determined whether IORT provides any benefit for OS in this patient population (gastric cancer patients) when used with EBRT. Further study is needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have soft tissue sarcomas who receive adjunctive IORT, the evidence includes a systematic review, a small RCT, and several nonrandomized comparative studies. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. Overall, the study quality is low. The limited data suggest that IORT might improve local control and OS but adverse events might outweigh any treatment benefit. RCTs are needed to determine the risks and benefits of IORT for soft tissue sarcomas with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have gynecologic cancers who receive adjunctive IORT, the evidence includes a nonrandomized trial and case series. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. The contribution of adjuvant IORT cannot be determined from the available literature. There is no evidence that IORT improves survival rates, and there may be severe complications related to the therapy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have head and neck cancers who receive adjunctive IORT, the evidence includes case series. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. The strongest evidence is from a retrospective analysis of patients who had recurrent salivary gland carcinomas and were at risk of radiation toxicity due to prior treatment with EBRT. Some patients received IORT plus salvage surgery, and multivariate analysis found that the use of IORT was a significant predictor of improved outcomes. Although these findings suggested an improvement in health outcomes for head and neck cancers that cannot be treated with EBRT due to toxicity, there was a high-risk of selection bias in this study. Comparative trials are needed to determine the efficacy of IORT with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have pancreatic cancer who receive adjunctive IORT, the evidence includes large case series, cohort studies, and systematic reviews of these studies. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. The systematic reviews found no evidence that IORT was more effective than other therapies in treating pancreatic cancer. No evidence was identified that evaluated outcomes when IORT was and was not added to multimodal therapy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have RCC who receive adjunctive IORT, the evidence includes case series. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. No controlled trials were identified to determine whether adjunctive IORT improves health outcomes when added to multimodal therapy with surgical resection and EBRT. Grade 3 or higher toxicity after IORT has been reported in a substantial percentage of patients. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have glioblastoma or neuroblastoma or fibromatosis who receive adjunctive IORT, the evidence includes case series. The relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. Compared with other therapies, it is unclear whether IORT improves OS. However, compared with historical controls, IORT for patients with previously untreated malignant gliomas had no survival benefit when given in conjunction with multimodal therapy. In addition, complication rates may be high. Comparative trials are needed to evaluate the safety and efficacy of this treatment modality. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Supplemental Information**

**Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests from Blue Cross Blue Shield Association, input was received from 1 physician specialty society and 2 academic medical centers (6 reviewers) in 2009. Input was quite variable, with some supporting use of intraoperative radiotherapy for multiple indications and others considering it investigational. The strongest support was for rectal cancer.

**Practice Guidelines and Position Statements**

**National Comprehensive Cancer Network**

Table 2 lists the National Comprehensive Cancer Network guidelines on the use of intraoperative radiotherapy for the treatment of various cancers relevant to this evidence review.

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Version</th>
<th>Recommendation</th>
<th>COR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical</td>
<td>v.4.2019</td>
<td>IORT &quot;is particularly useful in patients with recurrent disease within a previously radiated volume. During IORT, overlying normal tissue (such as bowel or other viscera) can be manually displaced from the region at risk.&quot;</td>
<td>3</td>
</tr>
<tr>
<td>Colon</td>
<td>v.2.2019</td>
<td>IORT &quot;may be considered for patients with T4 or recurrent cancers as an additional boost.&quot;</td>
<td>2A</td>
</tr>
<tr>
<td>Gastric</td>
<td>v.2.2019</td>
<td>IORT is currently not recommended</td>
<td>NA</td>
</tr>
<tr>
<td>Head/neck</td>
<td>v.1.2019</td>
<td>IORT is not addressed</td>
<td>NA</td>
</tr>
<tr>
<td>Ovarian</td>
<td>v.1.2019</td>
<td>IORT is not addressed</td>
<td>NA</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>v.2.2019</td>
<td>&quot;Overall, there is no clear established role for IORT in patients with pancreatic cancer, and the panel believes it should only be performed at specialized centers.&quot;</td>
<td>NA</td>
</tr>
<tr>
<td>Rectal</td>
<td>v.2.2019</td>
<td>IORT &quot;if available, may be considered for very close or positive margins after resection, as an additional boost, especially for patients with T4 or recurrent cancers.&quot;</td>
<td>2A</td>
</tr>
<tr>
<td>Renal</td>
<td>v.1.2020</td>
<td>IORT is not addressed</td>
<td>NA</td>
</tr>
<tr>
<td>Soft tissue sarcoma</td>
<td>v.2.2019</td>
<td>For patients with resectable disease, consider boost with IORT for positive margins &quot;10-12.5 Gy for microscopic residual disease&quot; and &quot;15 Gy for gross residual disease&quot;</td>
<td>2A</td>
</tr>
</tbody>
</table>
| Uterine     | v.2.2018 | • For patients with "locoregional recurrence ... [and] prior RT to site of recurrence ... surgical exploration + resection ±IORT" may be considered.  
• For patients with "radiologically isolated vaginal/pelvic recurrence ... surgical exploration + resection ±IORT ±systemic therapy" may be considered. | 3 |

**COR:** category of recommendation; Gy: gray; IORT: intraoperative radiotherapy; NA: not applicable; RT: radiotherapy.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.
Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 3.

Table 3. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td>A Multicenter Randomized Phase III Trial on INtraoperative Radiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)</td>
<td>314</td>
<td>Feb 2021</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References


**Documentation for Clinical Review**

*Please provide the following documentation (if/when requested):*

- History and physical and/or consultation notes including:
  - Cancer description, location and tumor staging
  - Previous treatment(s) and response(s)
  - Radiology report(s)
  - Pathology report(s)
- Intraoperative radiation treatment report(s)/note(s)
  - Operative report(s) including: Description and location of cancer

**Post Service**

- Results/reports of tests performed
- Procedure report(s)

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**MN/IE**

The following services may be considered medically necessary in certain instances and investigational in others. Services may be considered medically necessary when policy criteria are met. Services may be considered investigational when the policy criteria are not met or when the code describes application of a product in the position statement that is investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>77424</td>
<td>Intraoperative radiation treatment delivery, x-ray, single treatment session</td>
</tr>
</tbody>
</table>
Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/05/2012</td>
<td>New Policy Adoption BCBSA Medically necessary criteria revised</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>07/31/2015</td>
<td>Coding update</td>
<td>Administrative Review</td>
</tr>
<tr>
<td>01/01/2016</td>
<td>Policy title change from Intraoperative Radiation Therapy (IORT) with External Beam Policy revision with position change effective 3/01/2016</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>03/01/2016</td>
<td>Policy revision with position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>02/01/2017</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>02/01/2018</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>09/01/2018</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
<tr>
<td>09/01/2019</td>
<td>Policy revision without position change</td>
<td>Medical Policy Committee</td>
</tr>
</tbody>
</table>

Definitions of Decision Determinations

**Medically Necessary:** A treatment, procedure, or drug is medically necessary only when it has been established as safe and effective for the particular symptoms or diagnosis, is not investigational or experimental, is not being provided primarily for the convenience of the patient or the provider, and is provided at the most appropriate level to treat the condition.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.
Questions regarding the applicability of this policy should be directed to the Prior Authorization Department. Please call (800) 541-6652 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.